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 Little work on the concordance of genetic variation between PTSD or anxiety 
disorders and brain volume has been conducted 
 There is evidence for genome wide concordance between genetic risk factors for 
anxiety disorders and smaller amygdala volume  
 A genetic variant that contributes to both reduced putamen volume and PTSD plays a 
key role in the glutamatergic system 
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Background:  There have been considerable recent advances in understanding the genetic 
architecture of anxiety disorders and posttraumatic stress disorder (PTSD), as well as the 
underlying neurocircuitry of these disorders.  However, there is little work on the 
concordance of genetic variations that increase risk for these conditions, and that influence 
subcortical brain structures. We undertook a genome-wide investigation of the overlap 
between the genetic influences from single nucleotide polymorphisms (SNPs) on volumes of 
subcortical brain structures and genetic risk for anxiety disorders and PTSD. 
Method:  We obtained summary statistics of genome-wide association studies (GWAS) of 
anxiety disorders (Ncases=7016, Ncontrols=14745), PTSD (European sample; Ncases=2424, 
Ncontrols=7113) and of subcortical brain structures (N=13171).  SNP Effect Concordance 
Analysis (SECA) and Linkage Disequilibrium (LD) Score Regression were used to examine 
genetic pleiotropy, concordance, and genome-wide correlations respectively. SECAs 
conditional false discovery was used to identify specific risk variants associated with anxiety 
disorders or PTSD when conditioning on brain related traits.  
Results:  For anxiety disorders, we found evidence of significant concordance between 
increased anxiety risk variants and variants associated with smaller amygdala volume. 
Further, by conditioning on brain volume GWAS, we identified novel variants that associate 
with smaller brain volumes and increase risk for disorders: rs56242606 was found to increase 
risk for anxiety disorders, while two variants (rs6470292 and rs683250) increase risk for 
PTSD, when conditioning on the GWAS of putamen volume. 
Limitations: Despite using the largest available GWAS summary statistics, the analyses were 
limited by sample size. 
Conclusions:  These preliminary data indicate that there is genome wide concordance 













which is consistent with research that supports the involvement of the amygdala in anxiety 
disorders.  It is notable that a genetic variant that contributes to both reduced putamen 
volume and PTSD plays a key role in the glutamatergic system. Further work with GWAS 
summary statistics from larger samples, and a more extensive look at the genetics underlying 



















Anxiety disorders and posttraumatic stress disorder (PTSD) are the most common class of 
mental disorders (Kessler et al., 2010) and are among the most debilitating (Costello et al., 
2005). In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5), a decision was taken to move PTSD into a separate chapter on trauma- and 
stressor-related disorders, but at the same time it has been emphasized that there are 
important overlaps in phenomenology and psychobiology across these conditions (Friedman 
et al., 2011; Hoge et al., 2016).  Although many considerations contribute to nosological 
decisions, ongoing work on the neurogenetics and neurocircuitry of these conditions is 
needed.  
There are significant genetic contributions to the etiology of these disorders with heritability 
estimates ranging between 10-50%  (Hettema et al., 2001; Otowa et al., 2016) and 15-52% 
(Duncan et al., 2017; Mataix-Cols et al., 2013), respectively. There have been significant 
recent advances in the understanding of the genetic architecture of anxiety disorders and 
PTSD. Several genome wide association studies (GWAS) have been undertaken in anxiety 
disorders; the largest included a total of 18,186 participants from the Anxiety Neurogenetics 
Study Consortium (ANGST). Taken together these suggest that variants affecting calcium 
signalling and transmembrane proteins, which are highly expressed in the brain, may play a 
role (Erhardt et al., 2012; Erhardt et al., 2011; Otowa et al., 2016; Otowa et al., 2009). The 
largest GWAS of PTSD to date included 20,070 participants from the Psychiatric Genomics 
Consortium-Posttraumatic Stress Disorder group (PGC-PTSD) found informative polygenic 
results such as evidence of PTSD heritability (15%) and overlapping genetic risk with other 













There have also been ongoing advances in understanding the neurocircuitry of anxiety 
disorders and PTSD. Large collaborations have formed to pool together resources and 
neuroimaging data for reliable and reproducible findings; these have emphasized structural 
and functional abnormalities of the amygdala in anxiety disorders (Bruhl et al., 2014; 
Hattingh et al., 2013; Krain et al., 2008; Massana et al., 2003; Milham et al., 2005), although 
several other regions have also been implicated in individual studies, including smaller grey 
matter volumes in the bilateral dorsal and rostral anterior cingulate cortices, bilateral 
posterior part of the anterior cingulate cortex, and left lenticular nucleus (Radua et al., 2010). 
Smaller hippocampal volume has been identified in a number of PTSD studies as well as 
structural anomalies in the dorsal and rostral anterior cingulate cortices, ventromedial 
prefrontal cortex, amygdala and insula (Gilbertson et al., 2002; Karl et al., 2006; Logue et al., 
2018).  
Relatively little work to date has, however, focused on examining the genetic overlap 
between risk for disease and risk for altered brain structure. Exploring genetic correlations 
and concordance between brain structure and genetic risk for these conditions will provide 
insight into the pathways affected by the underlying biology of the disorders. The Enhancing 
Neuroimaging Genetics through Meta-analysis (ENIGMA) consortium performed a GWAS 
of structural brain MRI scans of 30,717 individuals (Hibar et al., 2015). This study identified 
novel genetic variants associated with the volumes of the putamen, caudate nuclei, 
hippocampi as well as the full intracranial volume (Hibar et al., 2015). 
ANGST, PGC and ENIGMA freely release summary results of their GWAS, which provides 
an opportunity to examine the relationship between GWAS data in anxiety disorders and 
PTSD with the genetic contributions to brain volume.   Using SNP Effect Concordance 













concordance between OCD risk variants and variants associated with greater nucleus 
accumbens (P=2.0x10
-4
) and putamen volumes (P=8.0x10
-4
)(Hibar et al., 2018). Here we 
expand this analysis to anxiety disorders and PTSD, with the aim of assessing genetic 















2.1 Description of original association studies 
We analysed summary statistics from GWASs of the Anxiety NeuroGenetics STudy 
(ANGST), PGC-PTSD and the ENIGMA Consortium meta-analysis of subcortical brain 
volumes (Duncan et al., 2017; Hibar et al., 2015; Otowa et al., 2016). The anxiety disorder 
GWAS was based on case-control samples from 7 European groups contributing to the 
ANGST Consortium, totalling 7,016 cases and 14,745 controls (Otowa et al., 2016). The 
ANGST studies included participants with generalised anxiety disorder, panic disorder, social 
phobia, agoraphobia and specific phobias. Two phenotypic approaches were applied: 
quantitative phenotypic factor scores and categorical case-control comparisons, resulting in 
two sets of GWAS results. The PGC-PTSD GWAS was based on case-control samples from 
11 contributing groups (totalling 4,522 cases and 15,548 controls of which 87.7% were 
trauma-exposed) (Duncan et al., 2017). For the purposes of this study, we used the European 
Ancestry (EA) data, totalling 2,424 cases and 7,113 controls.  
The ENIGMA Consortium GWAS of subcortical brain volumes included a meta-analysis of 
50 cohorts (Hibar et al., 2015). These data comprised separate GWASs of seven subcortical 
brain volumes (nucleus accumbens, amygdala, caudate nucleus, hippocampus, globus 
pallidus, putamen, thalamus), and total intracranial volume. Summary statistics of the GWAS 
results were available from 13,171 subjects that made up the discovery sample.  Brain 
volume data were extracted following a harmonized protocol that uses validated, robust 
segmentation algorithms (Fischl et al., 2002) in order to ensure maximum cross-site 
comparability. All subjects were of European ancestry as verified by MDS analysis and 
GWAS test statistics were genome-controlled to adjust for spurious inflation factors. The 













neuropsychiatric disorders including anxiety, but diagnostic status was controlled for in the 
analysis (see Hibar et al., 2015 Methods, and Supplementary Table 1 for more details).  
 
2.2 Post-processing of genetic data 
After applying quality control and filtering rules to the imputed EA PTSD GWAS data, 
13,203,811 SNPs remained (see Duncan et al., 2017 Supplementary Materials for imputation 
and quality control details). For the anxiety GWAS data, 6,306,613 SNPs remained after 
filtering (see Otowa et al., 2016 Supplementary Methods for imputation and quality control 
details). Post-filtering for all 8 brain structures resulted in a final number of 8,398,366 SNPs 
for the imputed brain volume GWAS data (see Hibar et al., 2015 Methods for imputation and 
quality control details). To statistically compare the EA PTSD and eight brain volume 
GWASs, we used the 8,156,675 SNPs that passed quality control and filtering rules. To 
compare the anxiety GWAS with the ENIGMA GWASs, 5,642,909 SNPs were used for the 
factor score dataset, and 5,661,273 for the case control dataset. 
 
With each dataset, clumping was performed in PLINK (Purcell et al., 2007) to identify an 
independent SNP from every linkage disequilibrium (LD) block across the genome. This was 
done separately for each of the eight brain volume GWASs using an 500 Kb window, with 
SNPs in LD (r
2
 > 0,2), in the European reference samples from the 1000 Genome Project 
(Phase 1, version 3). The index SNP held the lowest p-value within each LD block, and all 
other SNPs in the LD block were dropped from the analysis. This resulted in a total of eight 
independent sets of SNPs, which represented the total variation explained across the genome 
conditioned on the significance in each brain volume GWAS. The corresponding PTSD and 
anxiety GWAS test statistic was determined for each independent SNP in the eight sets of 














2.3 Tests of pleiotropy and concordance 
SECA (Nyholt, 2014) was used to determine the extent of genetic overlap between PTSD or 
anxiety and each subcortical volume. A global test of pleiotropy was performed using a 
binomial test at 12 p-value levels: P ≤ (0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1). 
For a given subcortical region and PTSD or anxiety paired set, SNPs were ranked based on 
their p-value for association with each trait. The total number of SNPs overlapping between 
the two traits at each p-value threshold was determined and compared to the expected random 
overlap under the null hypothesis of no pleiotropy, using a binomial test. Each of the 12 p-
value levels in the subcortical volume GWAS was compared to all levels of the PTSD and 
anxiety GWASs (144 comparisons for PTSD and 144 comparisons for anxiety), and the 
number of comparisons with evidence of overlap was tallied at a nominally significant level 
of P ≤ 0.05. To evaluate the global level of pleiotropy we generated 10,000 permuted datasets 
for a given subcortical region versus PTSD or anxiety comparison and determined if the 
number of significance thresholds with genetic overlap was significantly greater than chance. 
 
In addition, concordance (the agreement in SNP effect directions across two traits) was 
estimated using SECA. A significant (P ≤ 0.05) positive or negative trend in the effect of the 
overlapping SNPs at each of the 12 p-value thresholds was estimated using a two-sided 
Fisher’s exact test. The direction of effect for each SNP was determined by the sign of the 
beta value of the SNP regression coefficient from each meta-analysis. In the anxiety disorder 
and PTSD GWASs, a positive beta value for a SNP was associated with an increased risk of 
developing anxiety disorders and PTSD (a negative beta value indicates a protective variant). 
A positive beta value for a SNP in a brain volume GWAS indicates that that SNP is 













with a reduction in brain volume). The global level of concordance between a given brain 
volume phenotype and anxiety disorders or PTSD was estimated by generating 10,000 
permuted datasets, repeating the Fisher’s exact test procedure, and determining if the number 
of significant overlapping thresholds was significantly greater than would be expected by 
chance (see Nyholt et al., 2014 for details of the SECA analysis). 
 
A Bonferroni-corrected significance level of P=0.05/2tests*8structures*2disorders=0.00156 
was set, based on the number of tests performed for pleiotropy and concordance between 
anxiety disorders and PTSD and all eight brain structures.  
 
2.4 Conditional false discovery rate to identify risk variants for anxiety disorders and PTSD  
We further examined if conditioning the anxiety disorders and PTSD GWAS results on 
genetic variants that influence subcortical regional volume could improve our ability to 
identify variants associated with these disorders (Andreassen et al., 2013). For a given 
subcortical volume phenotype, a subset of SNPs was selected at 14 false discovery rate 






, 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 
0.9, 1). The corresponding p-values for each SNP subset in the PTSD and anxiety GWASs 
were then observed, and the False Discovery Rate (FDR) method was applied to each subset 
of p-values in the PTSD and anxiety GWASs (Benjamini and Hochberg, 1995). Significance 
for individual SNPs was established if the p-value was lower than the significance threshold 
allowing for a FDR of 5% conditioned on any subset of SNPs from the subcortical volume 
GWASs. The LD-pruned data are still required for the conditional FDR SNP analysis 
because the size of an LD block can affect the ranking and re-ranking of SNPs under the 













SNPs in the LD block and should not necessarily be considered the causal variant or even the 
most significant SNP in terms of its overlap between traits. 
We identified variants in LD (r
2
 > 0.5) within 500kb either side of the significant SNPs using 
LDLink (https://ldlink.nci.nih.gov/) and SNiPA (https://snipa.helmholtz-
muenchen.de/snipa/). Genes that variants were either in, close to, or associated with were 
annotated using the Gene2Function link on FUMA (http://fuma.ctglab.nl/gene2func/) and 
Enrichr (http://amp.pharm.mssm.edu/Enrichr/), a pathway analysis software. Further, 
significant SNPs were annotated using Regulome (http://www.regulomedb.org/index), 
CADD (https://cadd.gs.washington.edu/), GTeX (https://gtexportal.org/home/) and HUGIn 
(https://yunliweb.its.unc.edu/hugin/) online software. 
 
2.5 Estimating genetic correlation using LD score regression 
We undertook LD score regression (LDSR), which estimates a genetic correlation between 
two traits based on the GWAS summary statistics of each trait analysed separately (Bulik-
Sullivan et al., 2015a; Bulik-Sullivan et al., 2015b). LDSR estimates a genetic correlation 
with a fitted linear model of Z-scores obtained from the product of significance statistics for 
each SNP in a given set of GWAS results compared to the level of LD at a given SNP. SNPs 
in high LD are expected to have high Z-scores in polygenic traits with common genetic 
overlap (Bulik-Sullivan et al., 2015a; Bulik-Sullivan et al., 2015b). Similar to SECAs 
concordance test, the genetic correlation from LDSR incorporates the sign of the regression 
coefficients for each SNP tested in order to determine the direction (positive or negative) of 
the relation between traits. This amygdala GWAS has previously been shown to have 
insufficient power for LDSR (Franke et al., 2016). As the amygdala is one of the main 
structures of interest for anxiety disorders and PTSD, LDSR was not our main analytic 















3.1 Evidence for pleiotropy between subcortical volume and anxiety disorders and PTSD  
 
Using SECA, we did not find significant evidence of global pleiotropy (regardless of effect 
direction) for either anxiety disorders or PTSD in any of the subcortical structures studied 
after correction for multiple comparisons (Table 1).  
For anxiety disorders, the evidence of pleiotropy was suggestive between variants affecting 
amygdala volume and risk using factor score analysis (Table 1, p=0.004), as well as for 
between variants affecting putamen volume and risk using case-control analysis (Table 1, 
p=0.01), but this was not significant after correction for multiple testing. For PTSD, 
suggestive evidence of pleiotropy was observed between variants affecting intracranial 
volume and risk for PTSD (Table 1, p=0.03), but was not significant after correction for 
multiple testing.  
 
3.2 Evidence for concordance between the genetics underlying brain volume and anxiety 
disorders or PTSD  
We found significant evidence of concordance (same SNP, direction of effect) between risk 
variants for anxiety disorders brain volumes. Specifically, we found negative concordance 
such that variants that increase risk for anxiety disorders, decrease the volume of the 
amygdala; this was found using both factor score analysis (Table 2, p=0.0001) and case-
control analysis (Table 2, p=0.0001). While we observed some evidence for negative 
concordance in anxiety disorders genetic risk and variants associated with putamen volume 
when using the factor score dataset (Table 1, p=0.008) and nucleus accumbens volume when 
using the case-control dataset (Table 2, p=0.002), these findings were not significant after 













For PTSD genetic risk, suggestive negative concordance was found for variants associated 
with amygdala volume (p=0.016), hippocampal volume (p=0.048) and thalamic volume 
(p=0.01) (Table 2), but these were not significant after correction for multiple testing. 
 
3.3. Genetic variants influencing brain volume regions provide improved ability to detect 
anxiety risk variants 
A conditional false discovery rate (FDR) analysis was performed to separately condition the 
anxiety disorder and PTSD GWASs on each of the eight brain volume GWASs. Using the 
factor score dataset for anxiety disorders, we identified three novel variants influencing risk 
for anxiety disorders when conditioning on the GWAS of amygdala volume (rs77520376, 
q=0.028), hippocampal volume (rs78587286, q=0.029) and putamen volume (rs56242606, 
q=0.04) (Table 3a). Furthermore, using the case-control GWAS we found variants 
influencing anxiety disorders when conditioning on the GWAS of the hippocampal volume 
(rs28373923, q=0.032), pallidum volume (rs12751736, q=0.041) and thalamic volume 
(rs2740360, q=0.01) (Table 3b).  
For PTSD, two variants were found to significantly influence disorder when conditioned on 
putamen volume (rs6470292, q=0.048; rs683250, q=0.048) (Table 4). 
SNP-based annotation showed there was minimal binding evidence, no associated deleterious 
effect, and few single tissue eQTLs for the significant variants (Supplementary Material). 
Expression, gene set and pathway analysis of genes associated with significant variants and 
variants in LD are available in the Supplementary Materials. 
 
3.4 LD score regression 
LDSR findings were consistent with SECA findings for both anxiety disorders and PTSD. A 













observed (Table 5, p=0.007, rg=-0.48; Table 6), while a positive genetic correlation was 
suggested between risk for PTSD and caudate volume (Table 7, p=0.093, rg=0.35). 
4. Discussion 
The key findings of this study were 1) a significant concordance between risk variants for 
anxiety disorders and variants that decrease the volume of the amygdala (p=0.0001) using 
both factor score and case-control methods for assessing anxiety, and 2) a variant influencing 
decreased amygdala volume, rs77520376, was significantly associated with anxiety 
disorders. Although PTSD concordance findings were non-significant after multiple 
corrections, two variants associated with decreased putamen volume (rs6470292 and 
rs683250) were also associated with PTSD. 
The anxiety disorder findings are consistent with previous work, which has identified 
decreased grey matter volumes in the amygdala amongst patients with social anxiety disorder 
(Irle et al., 2010) and panic disorder (Asami et al., 2008; Hayano et al., 2009; Massana et al., 
2003). There is, however, also evidence of increased amygdala volume in patients with 
anxiety disorders (Roth et al., 2018; Schienle et al., 2011; van der Plas et al., 2010). 
Involvement of the amygdala in anxiety disorders is further supported by functional 
neuroimaging studies. Hyperactivation of the amygdala in response to various stimuli 
compared to healthy controls has been observed (Guyer et al., 2008; Hattingh et al., 2013; 
Monk et al., 2008; van den Heuvel et al., 2005; Wendt et al., 2008), with decreases after 
successful treatment of specific phobia (Goossens et al., 2007; Ipser and Stein, 2012) and 
social anxiety disorder (Furmark et al., 2004; Labuschagne et al., 2010).  
The variant rs77520376, which is associated with risk for anxiety disorder and decreased 
amygdala, is located within an intron of the protocadherin-7 (PCDH7) gene. PCDH7 plays a 













including neural migration, synaptogenesis and axonal growth (Pham et al., 2016). Variants 
within PCDH7 have been associated with a number of psychiatric disorders, with trending 
significant associations with PTSD (Ashley-Koch et al.), bipolar disorder (Le‐ Niculescu et 
al., 2009) and epilepsy (Poduri, 2015). Little information is available on this variant, and 
further attention to its role across a range of psychiatric phenotypes may be useful. 
SECA and LD score regression results found marginal significance of putamen volume 
association with anxiety disorders and PTSD. However, conditioning of anxiety and PTSD 
GWAS results on genetic variants that influence brain volume showed one variant 
(rs56242606) significantly associated with decreased putamen volume and anxiety disorders, 
and two variants (rs6470292, rs683250) significantly associated with decreased putamen 
volume and PTSD. The variant rs56242606 is located on an intron within the VWDE gene, 
which is in a region of significance recently shown to be associated with anxiety disorders 
(Purves et al., 2017). Two significant eQTL associations for this variant and VWDE were 
observed (Supplementary Material). The variant, rs683250, associated with decreased 
putamen volume and PTSD, is found within the DLG2 gene, which encodes a protein 
involved in nervous system development, N-methyl-D-aspartate (NMDA) receptor signalling 
and glutamate receptor binding. NMDA receptors play a central role in modulating fear, 
anxiety, depression and PTSD (Barkus et al., 2010; Pitman et al., 2012; Yamamoto et al., 
2007).  
Two additional observations in this study should be considered. First, there were 
inconsistencies in the results of pleiotropy and concordance for both anxiety disorders and 
PTSD analyses. Thus, while there was significant concordance between anxiety disorders and 
amygdala volume, significant pleiotropy was not observed. Whereas pleiotropy indicates that 













specific decrease or increase in a particular subcortical structure. The anxiety and amygdala 
findings, where concordance is significant and pleiotropy is not, suggest those SNPs that 
contribute to concordance have predominantly positive or negative effect sizes. Second, there 
are discrepancies between the findings of factor score analysis and case control analysis; 
although this is not unexpected given the differences in these approaches, it again suggests 
that even larger sample sizes would be useful. 
Indeed, a number of limitations of this study should be emphasized.  First, despite using the 
largest sample sizes from the brain volume, anxiety and PTSD GWASs to date, false negative 
findings due to insufficient power cannot be excluded. Second, the relatively small samples 
do not allow for analyses to be stratified by sex; these may be useful given heritability 
differences in PTSD in females (29%) compared to males (7%). Third, in theory, the analysis 
could be biased if overlapping participants were present in the studies contributing to the 
consortia. LDSR takes possible overlap across studies into account. The relative similarity 
between the LDSR results and the concordance results therefore suggests that such overlap is 
likely to be minimal.  Fourth, the ENIGMA GWASs of brain volumes contain cohorts with 
healthy controls as well as patients diagnosed with neuropsychiatric disorders (including 
anxiety, Alzheimer’s disease, attention-deficit/hyperactivity disorder, major depression, 
bipolar disorder, epilepsy, and schizophrenia), which may bias the interpretation of our 
findings and how they relate to anxiety disorders and PTSD. However, the brain volume 
GWASs controlled for diagnostic status, and a direct comparison of the GWAS summary 
statistics between the full ENIGMA results (including patients) and a subset of ENIGMA 
results (excluding patients) showed that they were very highly correlated (Pearson’s r > 0.99) 
for all brain traits (Hibar et al., 2015).  This suggests that the pattern of effects in the brain 
volume GWAS is not likely driven by disease status. Fifth, the relationship between genetic 













confounders, including environmental factors such as stress and medication effects, which 
have effects on brain volume and disease risk independent of genetics (Navari and Dazzan, 
2009). Discovering the pathway by which gene variants influencing brain volume also create 
risk for anxiety disorders and PTSD may be hindered by environmental factors, which might 
obscure genetic relationships. However, this endeavour to find the genetic overlap between 
brain volume and disorder risk using the largest datasets to date shows important and 
promising insights suggesting that our understanding may only be improved when further 
incorporating environmental influences.  
The analyses here complement previous work on OCD, where we found significant positive 
concordance between OCD risk variants and variants that increase the volume of the nucleus 
accumbens (P = 2.0 x 10
-4
) and variants that increase the volume of the putamen (P = 8.0 x 
10
-4
)(Hibar et al., 2018).  Investigation of the overlap in genetic variants associated with 
disorder risk and subcortical neurocircuitry may provide information that could help clarify 
how anxiety disorders, PTSD, and OCD are related to one another. The findings here 
arguably support the decision to separate out anxiety disorders and trauma- and stressor-
related disorders from obsessive-compulsive related disorders (OCRD) in the fifth edition of 
the DSM-5 (American Psychiatric Association, 2013; Möller et al., 2015). At the same time, 
we would emphasize that decisions about the DSM-5 meta-structure are complex and a range 
of other data are needed to inform the debate (Stein, 2008; Stein et al., 2011).  
This work is the first to show an overlap between genetic risk for anxiety disorders and brain 
circuitry.  The negative genetic concordance between both measures of anxiety and amygdala 
volume is consistent with a broad range of previous work implicating the amygdala as a 
critical region for anxiety disorders (Shin and Liberzon, 2009).  Emerging collaborations and 













enhance statistical power in future iterations of this analysis.  Future work focusing on a 
range of other methodologies to assess genetic overlap may also be useful, following along 
the lines of recent work in schizophrenia (Franke et al., 2016; Lee and Huang, 2016). Such 
studies have used partitioning-based heritability analysis (Yang et al., 2011) and conjunction 
analysis (Nichols et al., 2005) to identify genetic variants associated with both schizophrenia 
risk and altered brain volumes, and such approaches, together with analyses such as 
Mendelian Randomization, may also be useful in future work on anxiety disorders and PTSD, 
when more powerful GWASs summary statistics are available from larger samples. 
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Bonferroni corrected p-value at 0.05/32 = 0.00156. 











Intracranial volume 1 (1-1) 0.159 (0.152-0.167) 0.0333 (0.3-0.037)** 
Accumbens 1 (1-1) 1 (1-1) 1 (1-1) 
Amygdala 0.0038 (0.00277-0.00521)** 0.297 (0.288-0.306) 1 (1-1) 
Caudate 0.0926 (0.0871-0.0984) 0.305 (0.296-0.314) 0.1640 (0.156-0.171) 
Hippocampus 1 (1-1) 0.152 (0.145-0.159) 0.3120 (0.303-0.321) 
Pallidum 1 (1-1) 1 (1-1) 0.3010 (0.292-0.31) 
Putamen 1 (1-1) 0.0101 (0.00832-0.0123)** 1 (1-1) 






















value at 0.05/32 = 0.00156. 











Intracranial volume 1 (1-1), + 0.257 (0.249-0.266), - 0.0852 (0.0799-0.0908), - 













)***, - 0.0162 (0.0139-0.0189)**, - 
Caudate 1 (1-1), + 0.139 (0.132-0.146), - 0.0555 (0.0512-0.0602), + 
Hippocampus 1 (1-1), - 0.109 (0.103-0.116), - 0.0479 (0.0439-0.0523)**, - 





)**, - 0.218 (0.21-0.227), - 0.2160 (0.208-0.224), + 













Table 3. Significant variants associated with anxiety disorder risk when conditioning on brain volume GWAS. The chromosome (Chr) 
and base pair (BP) are given in h19b37 coordinates. The Effect in Brain and Effect in AD (anxiety disorders) are both given in terms of the 
effect allele (EA). The non-effect allele (NEA) is also shown. The allele frequency (Freq) corresponds to the effect allele. Tagging SNP 
corresponds to the most significant variant in a given LD block (if different from the SNP chosen based on clumping in the brain volume 
GWAS). 
a) Factor score dataset 
 
b) Case control dataset 
Brain volume SNP Chr BP EA NEA Freq Nearest Gene Distance to Gene Effect in Brain (SE) P-value in Brain Effect in AD (SE) P-value in 
AD 
q-value 
Amygdala rs77520376 4 30993011 A G 0.0897 PCDH7 Intronic variant 16.172 (4.67) 0.0005369 0.038 (0.009) 3.21x10-5 0.0281 
Hippocampus rs78587286 6 14266689 T C 0.0966 CD83 129kb 36.86 (7.88) 2.87x10-6 0.0246 (0.008) 0.001954 0.0293 
Putamen rs56242606 7 12421909 T C 0.9223 VWDE Intronic variant 33.199 (11.91) 0.005299 -0.0417 (0.009) 6.2x10-6 0.0402 
Brain volume SNP Chr BP EA NEA Freq Nearest Gene Distance to Gene Effect in Brain (SE) P-value in Brain Effect in AD (SE) P-value in 
AD 
q-value 
Hippocampus rs28373923 16 88815473 A G 0.0753 PIEZO1 Intronic variant -31.994 (12.04) 7.89x10-3 0.4193 (0.091) 4.56x10-6 0.0317 
Pallidum rs12751736 1 21851462 A G 0.2889 ALPL Intronic variant 8.669 (2.14) 5.1x10-5 0.108 (0.03) 0.0003394 0.0414 















Table 4. Significant variants associated with PTSD risk when conditioning on brain volume GWAS. The chromosome (Chr) and base pair 
(BP) are given in h19b37 coordinates. The Effect in Brain and Effect in post traumatic stress disorder (PTSD) are both given in terms of the 
effect allele (EA). The non-effect allele (NEA) is also shown. The allele frequency (Freq) corresponds to the effect allele. Tagging SNP 









Brain volume SNP Chr BP EA NEA Freq Nearest Gene Distance to Gene Effect in Brain (SE) P-value in Brain Effect in PTSD (SE) P-value in PTSD q-value 
Putamen rs6470292 8 125868043 A G 0.8155 MIR4662B 33kb -36.2473 (7.71) 2.55x10-6 -0.485 (0.048) 0.00184 0.0476 
















Table 5. Results of the comparison between each brain volume GWAS from ENIGMA with anxiety disorders GWAS (factor score dataset) 
using LD score regression  
Trait  Brain volume Rg (SE) Z-score P-value  
AD Intracranial volume 0.2672 (0.2158) 1.2378 0.2158 
Accumbens -0.1296 (0.3151) -0.4114 0.6808 
Amygdala NA NA NA 
Caudate -0.1024 (0.1749) -0.5856 0.5582 
Hippocampus 0.0628 (0.2206) 0.2847 0.7759 
Pallidum -0.2042 (0.2196) -0.9298 0.3525 
Putamen -0.4821 (0.1798) -2.6814 0.0073** 
Thalamus 0.0311 (0.2126) 0.1463 0.8837 
Bonferroni corrected p-value at 0.05/28 = 0.00178 
AD, anxiety disorders 















Table 6. Results of the comparison between each brain volume GWAS from ENIGMA with anxiety disorders GWAS (case-control dataset) 
using LD score regression 
 
 
Trait  Brain volume Rg (SE) Z-score P-value  
AD Intracranial volume 0.1565 (0.2191) 0.7141 0.4752 
Accumbens -0.2242 (0.3128) -0.7169 0.4734 
Amygdala NA NA NA 
Caudate -0.0389 (0.155) -0.2508 0.802 
Hippocampus -0.1072 (0.2188) -0.4897 0.6243 
Pallidum -0.0836 (0.2052) -0.4076 0.6835 
Putamen -0.2026 (0.1611) -1.2573 0.2086 
Thalamus -0.1075 (0.2288) -0.4696 0.6386 
 
 
Bonferroni corrected p-value at 0.05/28 = 0.00178 






















Table 7. Results of the comparison between each brain volume GWAS from ENIGMA with PTSD GWAS (subjects of European ancestry) 
using LD score regression 
 
Trait  Brain volume Rg (SE) Z-score P-value  
PTSD Intracranial volume -0.2115 (0.1679) -1.2599 0.2077 
Accumbens NA NA NA 
Amygdala NA NA NA 
Caudate 0.3512 (0.209) 1.6807 0.0928 
Hippocampus 0.0324 (0.2826) 0.1146 0.9088 
Pallidum 0.2972 (0.2594) 1.1457 0.2519 
Putamen 0.4021 (0.242) 1.6612 0.0967 
Thalamus -0.318 (0.351) -0.9058 0.365 
 
Bonferroni corrected p-value at 0.05/24 = 0.002 
 
